Biotech, VC, deals
Cambria Pharmaceuticals Reaps $5.4M Financing
Erik Mellgren 4/22/08
Cambria Pharmaceuticals of Woburn, MA, has received $5.4 in a Series A round joined by Biogen Idec New Ventures, CommonAngels, and several individual investors, the company announced today. Cambria aims to find new treatments for neurological disorders, especially ALS, also known as Lou Gehrig’s disease.
Share
